Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Sun Pharmaceutical Industries and LIB Therapeutics Inc. (LIB) today announced:
Lerodalcibep is approved in the EU under the brand name Lyrokaul for the treatment of adult patients with hypercholesterolaemia and mixed dyslipidaemia. In the United States, it is US FDA-approved under the brand name Lerochol as an adjunct to diet and exercise: to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).
The partnership helps address a significant global unmet need in cardiovascular care. Many patients at high or very high cardiovascular risk remain above recently updated and more globally harmonized 2026 guideline recommended LDL-cholesterol (LDL-C) goals despite treatment. In the DA VINCI observational study across 18 European countries, only 33% of patients assessed on stable oral lipid-lowering therapy achieved their risk-based 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) LDL-C goals.
Treatment guidelines now emphasise both additional LDL-C reductions and lower targets for patients at high and very high cardiovascular risk, with additional therapies when statins alone are insufficient. PCSK9 inhibitors provide the efficacy and safety to achieve these goals.4 This gap between treatment goals and real-world control reinforces the opportunity for Sun Pharma and LIB to broaden access to innovative lipid-lowering care across Europe and Sun's world-wide licensed markets.
The agreement establishes a significant new growth platform for Sun Pharma in a large and rapidly expanding market. According to IQVIA, the PCSK9 inhibitor market outside the United States and China reached US$ 3.7 billion in the period ending Q2 2026 (MAT Q2 2026), growing at 38% CAGR over the preceding two years. Europe alone accounted for US$ 2.9 billion PCSK9 inhibitor market in MAT Q2 2026.
LIB will receive an upfront and future milestone payments, together with royalties based on net sales in the licensed territories. Other terms of the agreement are confidential. Sun Pharma will be responsible for pursuing regulatory approvals in licensed territories where approval has not yet been obtained.
Sun Pharmaceutical Industries Ltd fell for a fifth straight session today. The stock is quoting at Rs 1873.4, down 0.66% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.4% on the day, quoting at 23541.1. The Sensex is at 75140.89, down 0.58%.Sun Pharmaceutical Industries Ltd has eased around 3.65% in last one month.Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has increased around 0.92% in last one month and is currently quoting at 26880.8, down 0.59% on the day. The volume in the stock stood at 6.8 lakh shares today, compared to the daily average of 15.37 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 1883.1, down 0.75% on the day. Sun Pharmaceutical Industries Ltd jumped 17.57% in last one year as compared to a 5.73% slide in NIFTY and a 20.8% spurt in the Nifty Pharma index.
The PE of the stock is 141.76 based on TTM earnings ending June 26.
Sun Pharmaceutical Industries and certain of its subsidiaries have been defendants in antitrust litigation in the United States relating to a 2008 patent litigation settlement agreement with Pfizer concerning generic Lipitor (Atorvastatin).
Plaintiffs alleged that the settlement unlawfully delayed generic competition for Lipitor and that absent the unlawful settlement, Lipitor would have entered the market earlier than it did.
The matter has been disclosed from time to time in the Company's financial statements.
The United States Court of Appeals for the Third Circuit has affirmed the order of the United States District Court granting summary judgment in its entirety in favour of the Company and its subsidiaries.
The Appellate Court has also affirmed the District Court's orders denying class certification as to the plaintiffs.
This decision represents a significant favourable development for the Company and its subsidiaries in the matter, and brings the litigation substantially to a close, subject to any further remedies that may be available to the plaintiffs under applicable law.
The plaintiffs had alleged that the settlement unlawfully delayed generic competition and that, without the agreement, generic Lipitor would have entered the US market earlier.
The US Court of Appeals for the Third Circuit has now affirmed the District Court’s summary judgment in its entirety in favour of Sun Pharma and its subsidiaries, while also upholding the District Court’s denial of class certification to the plaintiffs.
'This decision represents a significant favourable development for the Company and its subsidiaries in the matter, and brings the litigation substantially to a close, subject to any further remedies that may be available to the plaintiffs under applicable law,' Sun Pharma said in a statement.
As per media reports, the ruling is significant because the litigation had remained a long-standing legal overhang following Sun Pharma’s acquisition of Ranbaxy in 2014.
The Third Circuit’s decision effectively removes the principal claims against Sun Pharma in this matter, the reports added.
Sun Pharmaceutical Industries is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and active pharmaceutical ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world, with trading and other incidental and related activities extending to the global market. It is the largest pharmaceutical company in India.
The company had reported a 27.04% jump in consolidated net profit to Rs 2,894.79 crore for the quarter ended 30 June 2026 (Q1 FY27), compared with Rs 2,278.63 crore in the corresponding quarter last year. Revenue from sales climbed 10.14% YoY to Rs 15,183.55 crore in Q1 FY27.
The scrip shed 0.58% to currently trade at Rs 1913.70 on the BSE.
Profit before exceptional items and tax rose 7.82% to Rs 4,302.90 crore from Rs 3,990.77 crore a year earlier. The company reported exceptional items of Rs 204.09 crore during the quarter, including a charge of Rs 167 crore towards due diligence, legal, filing and other transaction-related expenses incurred for the proposed acquisition of Organon & Co. Sun Pharma said additional acquisition-related costs are expected in the coming quarters.
EBITDA increased 2.7% year-on-year to Rs 4,417.7 crore in Q1 FY27. However, the EBITDA margin contracted to 28.9% in Q1 FY27 from 31.1% in the year-ago period.
India continued to be the company's strongest market, with formulation sales rising 16% to Rs 5,474.9 crore, contributing 36.1% of consolidated sales.
In the United States, formulation sales declined 9.7% year-on-year to $427 million, as growth in the Innovative Medicines portfolio was partly offset by weakness in the generics business. The US business accounted for around 26.6% of consolidated sales.
Emerging Markets formulation sales rose 4.2% to $311 million, contributing 19.4% of total consolidated sales, while formulation sales in the Rest of the World stood at $218 million, accounting for 13.6% of consolidated sales.
Global Innovative Medicines sales climbed 12.8% YoY to $351 million during the quarter and contributed 21.9% of consolidated sales.
Research and development expenditure stood at Rs 826.4 crore, representing 5.4% of sales.
Kirti Ganorkar, managing director, said, “Our performance during the quarter was driven by strong momentum in India as well as Innovative Medicines, which delivered robust growth across the U.S. and international regions. Recent semaglutide approvals in India, Brazil and South Africa underscore our capabilities in developing complex peptide products for patients globally. Organon shareholders have approved the proposed acquisition by Sun, which is on track to close in early 2027.”
The counter declined 0.62% to close at Rs 1,988.25 on the BSE.
Sun Pharmaceutical Industries Ltd rose for a fifth straight session today. The stock is quoting at Rs 2033.1, up 1.6% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.35% on the day, quoting at 24401.75. The Sensex is at 78202.2, up 0.35%. Sun Pharmaceutical Industries Ltd has added around 8.94% in last one month.
Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has added around 5.81% in last one month and is currently quoting at 26346.05, up 1.14% on the day. The volume in the stock stood at 10.53 lakh shares today, compared to the daily average of 23.07 lakh shares in last one month.
The benchmark August futures contract for the stock is quoting at Rs 2037.9, up 1.53% on the day. Sun Pharmaceutical Industries Ltd is up 24.75% in last one year as compared to a 0.67% fall in NIFTY and a 21.06% fall in the Nifty Pharma index.
The PE of the stock is 163.06 based on TTM earnings ending March 26.
Sun Pharmaceutical Industries announced that the stockholders of Organon & Co. (Organon) have approved the proposals in connection with the previously announced merger transaction under which Organon is expected to become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA, Inc., an indirect wholly owned subsidiary of Sun Pharma.
The shareholder approval marks an important milestone towards completion of the proposed transaction. The acquisition remains subject to the satisfaction of the remaining customary closing conditions, including applicable regulatory approvals.